Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism FGF23 antagonists(Fibroblast growth factor 23 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Kidney Diseases | Preclinical | CA | 13 Sep 2024 | |
FGF23 positive Hypophosphatemia | Preclinical | CA | 13 Sep 2024 |